Johnson & Johnson (J&J) announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%. Domestic sales increased 14.9% and international sales increased 4.4%, reflecting operational growth of 5% and a negative currency impact of 0.6%.
“Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities,” said Alex Gorsky, chairman and CEO of Johnson & Johnson. “Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market.”
The company’s worldwide consumer division recorded sales of $3.7 billion for the second quarter 2014, representing an increase of 2.4% versus the prior year. This consisted of an operational increase of 3.6% and a negative impact from currency of 1.2%. For the worldwide consumer division, domestic sales decreased 0.5%, primarily reflecting the divestiture of the sanitary protection business; international sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.
Positive contributors to operational results were sales of the company’s Neutrogena and Aveeno skin care products and its baby care products, as well as its Tylenol and Motrin analgesics, over-the-counter upper respiratory medicines, and international sales of Listerine mouthwash and feminine protection products.
With these results, Johnson & Johnson increased its earnings guidance for full-year 2014 to $5.85–5.92 per share. The company’s guidance excludes the impact of special items.